CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer



Status:Active, not recruiting
Conditions:Prostate Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/21/2019
Start Date:September 10, 2013
End Date:February 15, 2022

Use our guide to learn which trials are right for you!

Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)

This randomized phase II trial studies how well glycosylated recombinant human interleukin-7
(CYT107) after vaccine therapy works in treating patients with castration-resistant prostate
cancer that has spread to other areas of the body or has not responded to at least one type
of treatment. Biological therapies, such as glycosylated recombinant human interleukin-7, may
stimulate the immune system in different ways and stop tumor cells from growing. Vaccines
made from white blood cells mixed with tumor proteins may help the body build an effective
immune response to kill tumor cells. It is not yet known whether glycosylated recombinant
human interleukin-7 works better with or without vaccine therapy in treating prostate cancer.

PRIMARY OBJECTIVES:

I. To determine whether CYT107 administration increases the vaccine-induced antigen-specific
T-cell immune response to the sipuleucel-T fusion protein vaccine construct prostatic acid
phosphatase granulocyte-macrophage colony-stimulating factor (PAP-GM-CSF) (PA2024).

SECONDARY OBJECTIVES:

I. To determine whether CYT107 administration increases the vaccine-induced antigen-specific
T-cell immune response to PAP.

II. To assess the character of the T-cell immune response to PAP and PA2024. III. To
determine whether CYT107 administration increases the vaccine-induced antigen-specific
antibody immune responses to PAP and PA2024.

IV. To quantify the effects of CYT107 on T-cell repertoire diversity. V. To assess the
effects of CYT107 on the immune competence of patients with advanced prostate cancer.

VI. To assess the clinical efficacy and tolerability of sipuleucel-T plus CYT107 compared
with sipuleucel-T alone.

OUTLINE: Patients are randomized to 1 of 2 cohorts.

COHORT I: Patients receive no treatment (observation) after completion of standard
sipuleucel-T therapy.

COHORT II: Patients receive glycosylated recombinant human interleukin-7 subcutaneously (SC)
every week for 4 weeks (on days 0, 7, 14, and 21) beginning 3-7 days after completion of
standard sipuleucel-T therapy. Treatment continues in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up for 53 weeks. Patients are
followed by phone, once a year, after completion of Week 53 for overall survival.

Inclusion Criteria:

- Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer
(mCRPC)

- Patients must have successfully completed therapy with sipuleucel-T within 3-7 days of
planned CYT107 study drug treatment

- Assessable disease with a positive bone scan and/or measurable disease on computed
tomography (CT) scan and/or magnetic resonance imaging (MRI) of the abdomen and pelvis

- Prior orchiectomy or must be on ongoing luteinizing hormone-releasing hormone (LHRH)
agonist or antagonist (e.g., degarelix) therapy

- No ongoing anti-androgen therapy; patients must be off anti-androgen therapy for at
least 30 days

- Patients receiving any other hormonal therapy, including any dose of megestrol acetate
(Megace), Proscar (finasteride), any herbal product known to decrease prostate
specific antigen (PSA) levels (e.g. saw palmetto, PC-SPES), or any systemic
corticosteroid, must discontinue the agent for at least 30 days prior to study
treatment

- Absolute neutrophil count (ANC) >= 1500/uL

- Bilirubin < 1.5 x upper limit of normal (ULN)

- Hemoglobin >= 10 g/dL

- Platelets >= 100,000/mcL

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN

- Creatinine clearance >= 60 mL/min by the Cockcroft-Gault equation

- Testosterone =< 50 ng/dL (documented at any time while on LHRH agonist or antagonists
or s/p orchiectomy)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or a Karnofsky
performance status of >= 80%

- Life expectancy of at least 6 months

- Prior local radiation therapy must be completed at least 30 days prior to enrollment
and the patient must have recovered from all toxicity

- Prior "systemic" radiopharmaceuticals (strontium, samarium, radium 223 dichloride)
must be completed >= 8 weeks prior to enrollment

- Patients must agree to use 2 methods of adequate contraception for the duration of
study participation, and for four months after discontinuing therapy

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Prior chemotherapy for castration resistant prostate cancer; neoadjuvant chemotherapy
and chemotherapy given for hormone sensitive prostate cancer are allowed

- Prior investigational immunotherapy

- Prostate cancer pain requiring regularly scheduled narcotics

- Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical
erosion on radiography > 50%) or spinal cord compression

- Current treatment with systemic steroid therapy (inhaled/topical steroids are
acceptable); systemic corticosteroids must be discontinued for at least 30 days prior
to first CYT107 injection

- Known central nervous system metastases

- Documented cirrhosis or documented acute hepatitis; Note: a positive hepatitis B
serology indicative of previous immunization (i.e., hepatitis B surface antibody
[HBsAb] positive and hepatitis B core antibody [HBcAb] negative), or a fully resolved
acute hepatitis B virus (HBV) infection is not an exclusion criterion

- History of severe asthma, as defined by prior or current use of systemic
corticosteroids for disease control, with the exception of physiological replacement
doses of cortisone acetate or equivalent, as defined by a dose of 10 mg or less

- Medical or psychiatric illness that would, in the opinion of the investigator,
preclude participation in the study or the ability of patients to provide informed
consent for themselves

- Cardiovascular disease that meets one of the following: congestive heart failure (New
York Heart Association class III or IV), active angina pectoris, or recent myocardial
infarction (within the last 6 months)

- Concurrent or prior malignancy except for the following:

- Adequately treated basal or squamous cell skin cancer

- Adequately treated stage I or II cancer from which the patient is currently in
complete remission

- Any other cancer from which the patient has been disease-free for 5 years

- Known human immunodeficiency virus (HIV) or other history of immunodeficiency
disorder; HIV-positive patients on combination antiretroviral therapy are ineligible

- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or medical (e.g. infectious) illness

- Any underlying medical or psychiatric condition, which in the opinion of the
investigator will make the administration of CYT107 hazardous or obscure the
interpretation of adverse events (AEs), such as a condition associated with frequent
diarrhea

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to CYT107

- Patients who have received prior immunosuppressive therapy within 30 days prior to
enrollment

- Active (as defined by requiring immunosuppressive therapy) or history of clinically
significant autoimmune disease (as defined by previously requiring immunosuppressive
therapy)

- Patients who have received hepatotoxic drugs less than 7 days prior to enrollment

- Patients who have received prior biologic agents less than 30 days prior to enrollment

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance with study
requirements

- Patients who have a history of any hematopoietic malignancy

- History of pulmonary disease such as emphysema or chronic obstructive pulmonary
disease (COPD), (forced expiratory volume [FEV] > 60% of predicted for height and age
required in patients with prolonged smoking history or symptoms of respiratory
dysfunction)
We found this trial at
17
sites
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Principal Investigator: Rhonda L. Bitting
Phone: 336-713-6771
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Evan Y. Yu
Phone: 206-288-1152
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Evan Y. Yu
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Omer Kucuk
Phone: 404-778-1900
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Lauren C. Harshman
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Russell Z. Szmulewitz
Phone: 773-834-7424
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: J. P. Monk
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
Principal Investigator: Frederick E. Millard
Phone: 858-822-5354
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: John D. Seigne
Phone: 800-639-6918
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Tanya B. Dorff
Phone: 323-865-0451
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: Leonard J. Appleman
Phone: 412-647-8073
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Lawrence Fong
Phone: 415-514-3160
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Francisco, California 94158
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials